A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease
Phase 1
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002337
- Lead Sponsor
- Otsuka America Pharmaceutical
- Brief Summary
To evaluate the safety and tolerability of four doses of oral vesnarinone in patients with advanced HIV disease.
- Detailed Description
Fourteen patients per dose level receive vesnarinone at 1 of 4 doses for 12 weeks. At least seven patients at a given dose level must have completed 4 weeks of treatment before dose is escalated in subsequent patients.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 56
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
AIDS Research Consortium of Atlanta
🇺🇸Atlanta, Georgia, United States